Clik here to view.
Critical Outcome’s cancer drug continues positive track record
Critical Outcome Technologies (TSX-V:COT) has obtained positive results from new animal studies with its COTI-2 oral drug candidate, demonstrating efficacy as a single agent and in combination with...
View ArticleClik here to view.
Novadaq highlights game changer for the OR
With adoption of its SPY imaging technologies growing in operating rooms across North America, Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has embarked on a long-term growth plan to image nerves and...
View ArticleClik here to view.
Roth starts TrovaGene at buy
Roth Capital Partners has initiated coverage of TrovaGene (NASDAQ:TROV) with a “buy” rating and 12-month price target of $11. The stock closed at a 52-week high of $6.91 on Wednesday. By leveraging its...
View ArticleClik here to view.
Dr. Manuel Hidalgo joins PharmaCyte SAB
Dr. Manuel Hidalgo, one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer, has joined PharmaCyte Biotech’s (OTCQB:PMCB) scientific advisory board. In a...
View ArticleClik here to view.
Rodman starts VolitionRx at buy
Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s...
View ArticleClik here to view.
Roth starts Bionomics at buy
Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday. “We believe a significant...
View ArticleClik here to view.
Soricimed posts positive SOR-C13 data in solid tumors
Closely-held Soricimed Biopharma has announced positive top-line results from a Phase 1 open-label, dose escalation study of its first-in-class peptide, SOR-C13, in subjects with advanced solid tumor...
View ArticleClik here to view.
In conversation with Paul Gunn
Paul Gunn As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005...
View ArticleClik here to view.
Soricimed announces members of CAB
Closely-held Soricimed Biopharma has announced the members of its newly formed Clinical Advisory Board (CAB). The CAB, comprising key thought leaders in the treatment of cancer and novel anti-cancer...
View Article
